teprotumumab subcutaneous / Xeris Biopharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
teprotumumab subcutaneous / Xeris Biopharma
HZNP-TEP-305, NCT06248619: A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

Recruiting
3
80
Japan, US, RoW
Teprotumumab, Placebo
Amgen
Thyroid Eye Disease
10/25
05/26
NCT06563856: A Study of TEPEZZA Subcutaneous Administration in Healthy Adults

Completed
1
37
US
TEPEZZA, HZN-001, EDP
Amgen
Bioavailability, Bioequivalence
05/21
05/21

Download Options